(vianews) - the market ended the session with ab science (ab.pa) jumping 13.36% to €3.06 on friday, following the last session's upward trend. cac 40 rose 0.91% to €7,233.91, following the last session's downward trend on what was a somewhat positive trend trading session today.
ab science's last close was €2.70, 71.63% under its 52-week high of €9.50.
about ab science
ab science s.a., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. its lead compound is the masitinib, a tyrosine kinase inhibitor that is in phase iii clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, alzheimer's, severe asthma, and mastocytosis diseases, as well as in phase ii clinical trial to treat covid-19. the company is also developing ab8939, a synthetic microtubule destabiliser for haematology indications. the company markets its masitinib under the masivet brand in europe. ab science s.a. was incorporated in 2001 and is headquartered in paris, france.
earnings per share
as for profitability, ab science has a trailing twelve months eps of €-0.36.
revenue growth
year-on-year quarterly revenue growth declined by 58.3%, now sitting on 958k for the twelve trailing months.
yearly top and bottom value
ab science's stock is valued at €3.06 at 21:30 est, way under its 52-week high of €9.50 and way above its 52-week low of €2.73.
volatility
ab science's last week, last month's, and last quarter's current intraday variation average was 2.36%, 0.13%, and 4.45%.
ab science's highest amplitude of average volatility was 3.89% (last week), 2.98% (last month), and 4.45% (last quarter).
more news about ab science (ab.pa).